TGTX Stock Analysis: Buy, Sell, or Hold?
TGTX - TG Therapeutics, Inc.
$29.43
-0.57 (-1.90%)
▼
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 02, 2026
29d
Smart Money Accumulation
TGTX is down 5.7% this week, but smart money is accumulating calls. Top strike: $37 2026-03-20 with 542 OI. Call ratio: 78% View Scanner →
Strength: 5.7/10
Get Alerted When TGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called TGTX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TGTX is fairly valued with market pricing in 1.1% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: TGTX is fairly valued with market pricing in 1.1% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$9.50
Based on -18.4% avg growth
INTRINSIC VALUE TODAY
$5.90
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TGTX is currently trading at $29.43, which is considered slightly low relative to its 30-day fair value range of $29.18 to $31.13. The stock's valuation (Forward PE: 16.9) is in line with its historical norms (16.3). At these levels, the market is pricing in 1.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TGTX is in a strong downtrend. The price is currently testing key support at $29.47. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $44.86 (+49.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TGTX is in a strong downtrend. The price is currently testing key support at $29.47. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $44.86 (+49.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$29.18 -
$31.13
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
80.5%
Protect Your Profits
Holding TGTX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 49.5% below Wall St target ($44.86)
- NEUTRAL: Market pricing in 1.1% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -5.7% 5-day decline
Fair Price Analysis
30-Day Fair Range
$29.18 -
$31.13
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$29.47
Resistance Level
$32.55
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
16.90
Wall Street Target
$44.86
(+49.5%)
Revenue Growth (YoY)
92.8%
Earnings Growth (YoY)
12050.0%
Profit Margin
84.1%
Valuation Premium vs History
+1.1% premium
PE vs Historical
16.9 vs 16.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.1%
(market-implied from PE analysis)
1-Year Target
$30.33
(+1%)
2-Year Target
$30.66
(+2%)
3-Year Target
$31.00
(+3%)
3-Yr Target (if PE normalizes)
(PE: 17→16)
PE COMPRESSION
$29.90
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: -40.8%)
$28.86
(+-4%)
Base:
(SPY PE: 16.9, Growth: -40.8%)
$21.87
(-27%)
Bear:
(PE: 14.4, Growth: -40.8%)
$18.59
(-38%)
📈
Valuation based on Current Earnings
Trailing PE: 10.94 | Current EPS (TTM): $2.77
Bull Case
$21.37
(-27%)
Analyst growth -35.9%, PE expands to 12.0
Base Case
$19.42
(-34%)
Market implied -35.9%, PE stable at 10.9
Bear Case
$20.61
(-30%)
Severe decline -20.0%, PE contracts to 9.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 5:27 AM ET
Data refreshes hourly during market hours. Next update: 6:27 AM
Data refreshes hourly during market hours. Next update: 6:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Sagar Lonial
SELL
20852 shares
2025-09-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$22 | 60 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1035 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$83 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 60 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
Advanced TGTX Option Strategies
Professional options setups generated by AI based on today's TGTX price and gamma walls.
